2427 related articles for article (PubMed ID: 24333502)
21. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
22. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
23. Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma.
Blachly JS; Baiocchi RA
Br J Haematol; 2014 Oct; 167(1):19-32. PubMed ID: 25100567
[TBL] [Abstract][Full Text] [Related]
24. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
25. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Andersen JN; Sathyanarayanan S; Di Bacco A; Chi A; Zhang T; Chen AH; Dolinski B; Kraus M; Roberts B; Arthur W; Klinghoffer RA; Gargano D; Li L; Feldman I; Lynch B; Rush J; Hendrickson RC; Blume-Jensen P; Paweletz CP
Sci Transl Med; 2010 Aug; 2(43):43ra55. PubMed ID: 20686178
[TBL] [Abstract][Full Text] [Related]
26. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
27. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
28. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
29. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.
O' Neill C
Exp Gerontol; 2013 Jul; 48(7):647-53. PubMed ID: 23470275
[TBL] [Abstract][Full Text] [Related]
30. Targeting mTOR in mantle cell lymphoma: current and future directions.
Smith SM
Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
[TBL] [Abstract][Full Text] [Related]
31. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
32. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
33. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
34. PI3K: a potential therapeutic target for cancer.
Chen Y; Wang BC; Xiao Y
J Cell Physiol; 2012 Jul; 227(7):2818-21. PubMed ID: 21938729
[TBL] [Abstract][Full Text] [Related]
35. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
36. New phosphatidylinositol 3-kinase inhibitors for cancer.
Bowles DW; Jimeno A
Expert Opin Investig Drugs; 2011 Apr; 20(4):507-18. PubMed ID: 21395485
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway.
Liu F; Gao S; Yang Y; Zhao X; Fan Y; Ma W; Yang D; Yang A; Yu Y
Oncol Rep; 2018 Mar; 39(3):1523-1531. PubMed ID: 29328421
[TBL] [Abstract][Full Text] [Related]
38. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
Barrett D; Brown VI; Grupp SA; Teachey DT
Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
[TBL] [Abstract][Full Text] [Related]
39. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.
Khan KH; Wong M; Rihawi K; Bodla S; Morganstein D; Banerji U; Molife LR
Oncologist; 2016 Jul; 21(7):855-60. PubMed ID: 27151652
[TBL] [Abstract][Full Text] [Related]
40. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
